Buprenorphine Hydrochloride/Naloxone Hydrochloride (Hebei Lisheng Pharmaceutical)

复方盐酸丁丙诺啡（改良新）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBuprenorphine Hydrochloride/Naloxone Hydrochloride (Hebei Lisheng Pharmaceutical)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKappa opioid receptor antagonistsMu opioid receptor agonistsOpioid receptors antagonists
TargetsOpioid receptorsMu opioid receptorKappa opioid receptor
Therapy Area/IndicationsOpioid-Related Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesHebei Lisheng Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChina Institute Of Drug Dependence Peking UniversityHebei Lisheng Pharmaceutical Group Co Ltd
Active IndicationsN/A
Inactive IndicationsOpioid-Related Disorders

Other Information

ATC CodeN/A
Related LinksN/A